Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
KLRA Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kailera Therapeutics, Inc.
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Return on Equity (ROE)
-38.64%
TTM Avg
-84.50%
3Y Avg
-4452.86%
5Y Avg
-3001.92%
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Return on Equity (ROE)
9.00%
TTM Avg
8.29%
3Y Avg
7.90%
5Y Avg
8.39%
Market Cap
$1.42B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
Market Cap
$1.43B
Return on Equity (ROE)
N/A
TTM Avg
247.90%
3Y Avg
18.71%
5Y Avg
1.58%
Market Cap
$1.37B
Return on Equity (ROE)
N/A
TTM Avg
-244.46%
3Y Avg
-323.47%
5Y Avg
-258.47%
Market Cap
$1.44B
Return on Equity (ROE)
-7.08%
TTM Avg
-0.64%
3Y Avg
-1.30%
5Y Avg
-2.08%
Market Cap
$1.45B
Return on Equity (ROE)
23.70%
TTM Avg
9.74%
3Y Avg
8.98%
5Y Avg
11.20%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -38.64% | -84.50% | -4452.86% | -3001.92% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 9.00% | 8.29% | 7.90% | 8.39% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | N/A | 247.90% | 18.71% | 1.58% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A | -244.46% | -323.47% | -258.47% |
| Certara, Inc. (CERT)vs › | $1.44B | -7.08% | -0.64% | -1.30% | -2.08% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 23.70% | 9.74% | 8.98% | 11.20% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | -29.48% | -5.20% | -280.62% | -280.62% |
ROE
N/A
ROA
-21.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 41.79% |
